DEC 09, 2018 2:07 PM PST

Insect Venom Can Someday Combat Antibiotic-Resistant Infections

WRITTEN BY: Nouran Amin

Credit: National Geographic Kids

Insect venom, such as those secreted by wasps and bees, are considered an insect’s immune system defense because of its richness in bacterial killing compounds. These compounds have long inspired researchers to use them as an adaptive approach for deriving certain microbial peptides to create new drugs especially in the fight against antibiotic-resistant bacteria. However, it was no surprise to scientists when such venom was found to be toxic to humans—making it challenging for antibiotic drug development.

Fortunately, a recent study published in Nature Communications Biology, covers a systematic analysis on the antimicrobial peptides of a toxin secreted by a South American wasp known as Polybia paulista. The study revealed that variants of a certain peptide in that toxin are potent against bacteria but pose no toxic elements to human cells.

Learn more about how other research is combating antibiotic-resistant infections by turning insect venom into medicine:

Particularly, the MIT study was performed on mice where the best variant peptide was found to eliminate a strain of the bacterium, Pseudomonas aeruginosa, which is resistant to many antibiotics and the origin of many respiratory and urinary tract infections. The infection in mice was greatly reduced and eliminated when the peptide was administered at high doses.

“MIT engineers have developed new antimicrobial peptides based on a naturally occurring peptide produced by a South American wasp.”-MIT News

Image: Wikimedia, Charles J. Sharp via MIT

"After four days, that compound can completely clear the infection, and that was quite surprising and exciting because we don't typically see that with other experimental antimicrobials or other antibiotics that we've tested in the past with this particular mouse model," de la Fuente-Nunez says.

The venom-derived antimicrobial peptide is believed to eliminate bacteria by disrupting its cellular membrane.

"We've repurposed a toxic molecule into one that is a viable molecule to treat infections," explains MIT postdoctoral scientists and senior author of the study, Cesar de la Fuente-Nunez. "By systematically analyzing the structure and function of these peptides, we've been able to tune their properties and activity."

The isolated peptide contained only 12 amino acids making it feasible to alter it in order to increase the potent efficacy against eradicating bacteria but not harmful to human cells. To test for toxicity, the isolated peptide was exposed to cultured human embryonic kidney cells.

"It's a small enough peptide that you can try to mutate as many amino acid residues as possible to try to figure out how each building block is contributing to antimicrobial activity and toxicity," de la Fuente-Nunez says.

The authors of the study are hopeful that additional variants currently being created will be able to eradicate infections at lower doses. "I do think some of the principles that we've learned here can be applicable to other similar peptides that are derived from nature," says de la Fuente-Nunez. "Things like helicity and hydrophobicity are very important for a lot of these molecules, and some of the rules that we've learned here can definitely be extrapolated."

Source: MIT

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 13, 2020
APR 13, 2020
Computer Model Predicts How Drugs Affect Heart Rhythm
Cardiotoxicity, heart electrophysiology dysfunction or muscle damage,  is one of the most common reasons why drugs ...
APR 15, 2020
Chemistry & Physics
APR 15, 2020
Could this drug help people with SAD?
Have you ever been sad in the winter? If so, you’re not alone. Medaka fish feel it too. Seasonal affective disorde ...
APR 17, 2020
Drug Discovery & Development
APR 17, 2020
Gilead's Remdesivir Trial Sees Rapid Recoveries from COVID-19
Early results from a Chicago hospital treating patients with Gilead Sciences’ antiviral drug remdesivir for severe ...
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
MAY 06, 2020
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
MAY 28, 2020
Drug Discovery & Development
MAY 28, 2020
Trial for Arthritis Drug with Remdesivir to Beat COVID-19
Montefiore Health System and Albert Einstein College of Medicine in New York have teamed up to see how well remdesivir, ...
Loading Comments...